Furthermore, the KEYNOTE-040 trial also showed that patients with a tumor proportion score (TPS) ≥ 50%, indicating the percentage of tumor cells with membranous PD-L1 expression, had a significantly improved overall response and survival outcome with pembrolizumab [51]. The gene discussed is CD274; the disease is neoplasm.